Essais liés2clinical trials
VilleGuadalajaralocalisation
PaysMexicolocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT04548999

Ouvrir le site du centre

Essais cliniques associés

2
MoléculeIndication / populationPhaseNCTTitreStatut
Ocrelizumab Co-formulated With rHuPH20 SEP Phase 1 NCT07667322 OCARINA 3 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis ACTIVE_NOT_RECRUITING
Ocrelizumab SEP Phase 3 NCT04548999 GAVOTTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) ACTIVE_NOT_RECRUITING